Physiologically based pharmacokinetic modeling of cyclotrimethylenetrinitramine in male rats

被引:9
|
作者
Krishnan, Kannan [2 ]
Crouse, Lee C. B. [1 ]
Bazar, Matthew A. [1 ]
Major, Michael A. [1 ]
Reddy, Gunda [1 ]
机构
[1] USA, Ctr Hlth Promot & Prevent Med, Directorate Toxicol, Aberdeen Proving Ground, MD 21010 USA
[2] Univ Montreal, DSEST, Montreal, PQ, Canada
关键词
RDX; PBPK model; pharmacokinetics; HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE RDX; PARTITION-COEFFICIENTS; ORGANIC-CHEMICALS; RISK-ASSESSMENT; PREDICTION; HUMANS; PLASMA; BLOOD; SOILS;
D O I
10.1002/jat.1455
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
A physiologically based pharmacokinetic (PBPK) model for simulating the kinetics of cyclotrimethylene trinitramine (RDX) in male rats was developed. The model consisted of five compartments interconnected by systemic circulation. The tissue uptake of RDX was described as a perfusion-limited process whereas hepatic clearance and gastrointestinal absorption were described as first-order processes. The physiological parameters for the rat were obtained from the literature whereas the tissue: blood partition coefficients were estimated on the basis of the tissue and blood composition as well as the lipophilicity characteristics of RDX (logP = 0.87). The tissue: blood partition coefficients (brain, 1.4; muscle, 1; fat, 7.55; liver, 1.2) obtained with this algorithmic approach were used without any adjustment, since a focused in vitro study indicated that the relative concentration of RDX in whole blood and plasma is about 1:1. An initial estimate of metabolic clearance of RDX (2.2 h(-1) kg(-1)) was obtained by fitting PBPK model simulations to the data on plasma kinetics in rats administered 5.5 mg kg(-1) i.v. The rat PBPK model without any further change in parameter values adequately simulated the blood kinetic data for RDX at much lower doses (0.77 and 1.04 mg kg(-1) i.v.), collected in this study. The same model, with the incorporation of a first order oral absorption rate constant (K-a 0.75 h(-1)), reproduced the blood kinetics of RDX in rats receiving a single gavage dose of 1.53 or 2.02 mg kg(-1). Additionally, the model simulated the plasma and blood kinetics of orally administered RDX at a higher dose (100 mg kg(-1)) or lower doses (0.2 or 1.24 mg kg(-1)) in male rats. Overall, the rat PBPK model for RDX with its parameters adequately simulates the blood and plasma kinetic data, obtained following i.v. doses ranging from 0.77 to 5.5 mg kg(-1) as well as oral doses ranging from 0.2 to 100 mg kg(-1). Published in 2009 by John Wiley & Sons, Ltd.
引用
收藏
页码:629 / 637
页数:9
相关论文
共 50 条
  • [31] Elucidation of Carboxylesterase Mediated Pharmacokinetic Interactions between Irinotecan and Oroxylin A in Rats via Physiologically Based Pharmacokinetic Modeling
    Zhang, Jun
    Zhang, Yufeng
    Lai, Yuen Sze
    Song, Qianbo
    Xiao, Min
    Ji, Xiaoyu
    Yan, Xiaoyu
    Zuo, Zhong
    PHARMACEUTICAL RESEARCH, 2023, 40 (11) : 2627 - 2638
  • [32] Elucidation of Carboxylesterase Mediated Pharmacokinetic Interactions between Irinotecan and Oroxylin A in Rats via Physiologically Based Pharmacokinetic Modeling
    Jun Zhang
    Yufeng Zhang
    Yuen Sze Lai
    Qianbo Song
    Min Xiao
    Xiaoyu Ji
    Xiaoyu Yan
    Zhong Zuo
    Pharmaceutical Research, 2023, 40 : 2627 - 2638
  • [33] Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions
    Xia, Binfeng
    Heimbach, Tycho
    Lin, Tsu-han
    He, Handan
    Wang, Yanfeng
    Tan, Eugene
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1567 - 1582
  • [34] Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions
    Binfeng Xia
    Tycho Heimbach
    Tsu-han Lin
    Handan He
    Yanfeng Wang
    Eugene Tan
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1567 - 1582
  • [35] Physiologically based pharmacokinetic model for pralmorelin hydrochloride in rats
    Nasu, R
    Kumagai, Y
    Kogetsu, H
    Tsujimoto, M
    Ohtani, H
    Sawada, Y
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (10) : 1488 - 1494
  • [36] Physiologically based pharmacokinetic model for terbinafine in rats and humans
    Hosseini-Yeganeh, M
    McLachlan, AJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (07) : 2219 - 2228
  • [37] Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles
    Li, Min
    Zou, Peng
    Tyner, Katherine
    Lee, Sau
    AAPS JOURNAL, 2017, 19 (01): : 26 - 42
  • [38] Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling to the Rescue
    Tucker, Geoffrey T.
    ANESTHESIOLOGY, 2014, 120 (04) : 795 - 796
  • [39] Physiologically based pharmacokinetic modeling for tacrolimus in pig and human
    Tshinanu, Musuamba F.
    Mourad, M.
    Capron, A.
    Delattre, I. K.
    Verbeeck, R. K.
    Wallemacq, P.
    THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 536 - 536
  • [40] Pharmacokinetics and Physiologically-Based Pharmacokinetic Modeling of Nanoparticles
    Yang, Raymond S. H.
    Chang, Louis W.
    Yang, Chung Shi
    Lin, Pinpin
    JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2010, 10 (12) : 8482 - 8490